The recommendation addresses a long-standing treatment gap for patients facing bladder removal after standard therapy fails.

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with ...

Credit: Johnson & Johnson. Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet. Inlexzo is an intravesical gemcitabine ...

TARA-002 demonstrates high complete response rates in BCG-naïve NMIBC patients, with 72% achieving CR and 50% maintaining it ...

Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.

Anktiva is combined with BCG, or Bacillus Calmette-Guérin, an immunotherapy drug delivered to the bladder through a catheter. It’s intended for people who have non-muscle invasive bladder cancer, or ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

There’s a new twist in the fight against bladder cancer — and it’s delivering game-changing results. In a recent clinical trial, a pretzel-shaped device that slowly releases chemotherapy drugs ...

Inlexzo is an intravesical gemcitabine releasing system that is inserted directly into the bladder through a urinary catheter. The Food and Drug Administration (FDA) has approved Inlexzo ™ ...